Get the Stockscreener App
13.85
6.54%
0.85
Faeth Therapeutics Inc stock is traded at $13.85, with a volume of 219.73K.
It is up +6.54% in the last 24 hours and down -32.21% over the past month.
Sensei Biotherapeutics Inc is a clinical-stage biotechnology company engaged in the development of therapies targeting cancer through multi-node inhibition of oncogenic pathways. The company's lead program, PIKTOR, is an investigational oral combination therapy designed to inhibit multiple nodes of the PI3K/AKT/mTOR pathway and is being evaluated for the treatment of endometrial and breast cancers. In addition, the company is advancing other pipeline programs targeting tumor metabolism and signaling pathways.
See More
Previous Close:
$13.00
Open:
$15.21
24h Volume:
219.73K
Relative Volume:
3.99
Market Cap:
$18.59M
Revenue:
-
Net Income/Loss:
$-24.14M
P/E Ratio:
-0.9903
EPS:
-13.985
Net Cash Flow:
$-22.40M
1W Performance:
+6.54%
1M Performance:
-32.21%
6M Performance:
+75.54%
1Y Performance:
+130.83%
1-Day Range:
$13.76
$16.52
1-Week Range:
$10.78
$16.52
52-Week Range:
$5.8551
$36.76
Faeth Therapeutics Inc Stock (SNSE) Company Profile
Name
Faeth Therapeutics Inc
Sector
Industry
Phone
(240) 243-8000
Address
1405 RESEARCH BLVD, SUITE 125, ROCKVILLE
Compare SNSE vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SNSE
Sensei Biotherapeutics Inc
|
13.85 | 18.59M | 0 | -24.14M | -22.40M | -13.98 |
VRTX
Vertex Pharmaceuticals Inc
|
450.46 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.98 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
884.20 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
287.80 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
160.06 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Faeth Therapeutics Inc Stock (SNSE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-20-26 | Initiated | Leerink Partners | Outperform |
| Jun-02-25 | Resumed | H.C. Wainwright | Buy |
| May-14-24 | Initiated | Stephens | Overweight |
| Jul-01-21 | Downgrade | Berenberg | Buy → Hold |
| Jun-29-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Mar-01-21 | Initiated | Berenberg | Buy |
| Mar-01-21 | Initiated | Citigroup | Buy |
| Mar-01-21 | Initiated | Oppenheimer | Outperform |
| Mar-01-21 | Initiated | Piper Sandler | Overweight |
View All
Faeth Therapeutics Inc Stock (SNSE) Latest News
Sensei Biotherapeutics, Inc. will Change its Ticker to FTH from SNSE - marketscreener.com
SNSE Reiterates by BTIG -- Price Target Maintained at $55.00 - GuruFocus
Sensei Biotherapeutics Announces Name Change To Faeth Therapeutics - TradingView
Sensei Biotherapeutics, Inc. has Changed its Name to Faeth Therapeutics, Inc - marketscreener.com
Sensei Biotherapeutics, Inc. Appoints Brian Stephenson as Chief Financial Officer, Effective June 12, 2026 - marketscreener.com
Faeth Therapeutics (FTH) Transitions from Sensei Biotherapeutics (SNSE) - GuruFocus
Faeth Therapeutics Rebrands, Relocates and Overhauls Leadership - TipRanks
Sensei Biotherapeutics changes name to Faeth Therapeutics - Investing.com
Sensei Biotherapeutics changes name to Faeth Therapeutics By Investing.com - Investing.com Canada
Faeth Therapeutics (SNSE) adopts FTH ticker, installs new CEO and CFO - Stock Titan
Sensei Biotherapeutics Announces Name Change to Faeth Therapeutics, Focused on Advancing PIKTOR, an Oral Therapy Targeting One of the Most Frequently Altered Pathways in Cancer - Business Wire
[EFFECT] Sensei Biotherapeutics, Inc. SEC Filing - Stock Titan
Sensei Biotherapeutics (SNSE) president awarded 220,000 stock options at $29.89 - Stock Titan
Sensei Biotherapeutics grants director 12,500 options | SNSE Insider Trading - Stock Titan
Sensei Biotherapeutics (SNSE) director receives stock options on 12,500 shares - Stock Titan
Sensei Biotherapeutics (SNSE) Surges Over 20%: Key Levels to Watch After Strong RallyCovered Call Trade - newsline.com
SNSE Q1 2026 Earnings: Massive EPS Miss and Revenue Absence Highlight Clinical-Stage ChallengesEarnings Growth Analysis - newsline.com
SNSE Initiates Coverage by BTIG -- Price Target Announced at $55 - GuruFocus
Citi Maintains Sensei Biotherapeutics(SNSE.US) With Buy Rating, Maintains Target Price $55 - Moomoo
BTIG Research Initiates Coverage on Sensei Biotherapeutics With Buy Rating, $55 Price Target - marketscreener.com
BTIG Initiates Sensei Biotherapeutics(SNSE.US) With Buy Rating, Announces Target Price $55 - Moomoo
This Daktronics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Sahm
Sensei Biotherapeutics Overhauls Capital Structure at 2026 Meeting - TipRanks
Sensei Biotherapeutics (SNSE) registers 24.87M resale shares after Faeth deal - Stock Titan
Sensei Biotherapeutics (NASDAQ: SNSE) approves big share increase and new equity plans - Stock Titan
SNSE Stock Surges To 21-Month High – Everything To Know About Its Faeth Therapeutics Acquisition - Stocktwits
SNSE Q1 2026 Earnings: Massive EPS Miss Deepens Investor Concerns as Pre‑Revenue Biotech Faces HeadwindsAnnual Report - newsline.com
SNSE SEC FilingsSensei Biotherapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Millennium Management LLC Reduces Stake in Sensei Biotherapeutics Inc - GuruFocus
Sensei Biotherapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 4, 2026 - BioSpace
Cantor Fitzgerald Maintains Sensei Biotherapeutics(SNSE.US) With Buy Rating - Moomoo
Cantor Fitzgerald reiterates Sensei Biotherapeutics stock rating By Investing.com - Investing.com Canada
Millennium-led group reports 3.1% stake in Sensei Biotherapeutics (NASDAQ: SNSE) - Stock Titan
Most and least shorted healthcare stocks with market cap up to $2B at the end of May - Seeking Alpha
Sensei Biotherapeutics | SCHEDULE 13G/A: Others - Moomoo
Sensei Biotherapeutics, Inc. 2025 Annual Report: Cancer Therapeutics Pipeline, Regulatory Strategy, and Intellectual Property Overview - Minichart
Sensei Biotherapeutics (SNSE) revises 10-K to reflect Faeth deal, PIKTOR focus and $200M financing - Stock Titan
Sensei Biotherapeutics to register 24.9M shares after Faeth deal (SNSE) - Stock Titan
Cambrian BioPharma sells $500,542 of Sensei Biotherapeutics stock - Investing.com India
Cambrian BioPharma sells $500,542 of Sensei Biotherapeutics stock By Investing.com - Investing.com Australia
Insider Sell: Biopharma Cambrian Reduces Stake in Sensei Biother - GuruFocus
Dual Insider Moves Shake Up Sensei Biotherapeutics Investor Watch - TipRanks
Insider Sell: Biopharma Cambrian Reduces Stake in Sensei Biotherapeutics Inc (SNSE) - GuruFocus
Sensei Biotherapeutics ten percent owner James Peyer sells $500k in stock - Investing.com
Sensei Biotherapeutics Insiders Sold Shares Worth Over $1.0M - TradingView
Cambrian BioPharma sells 25,000 Sensei Biotherapeutics (SNSE) shares - Stock Titan
Ten percent owner of Sensei Biotherapeutics (SNSE) sells 25,000 shares in open market - Stock Titan
Top Biotech Gainers: REPL On Track, SNSE Awaits Phase 2 Data, Keep An Eye On CCCC, IMRX Soars - RTTNews
SNSE Initiated Coverage by Cantor Fitzgerald -- Rating Set to Ov - GuruFocus
Cantor Fitzgerald Initiates Sensei Biotherapeutics at Overweight - marketscreener.com
SNSE PE Ratio & Valuation, Is SNSE Overvalued - Intellectia AI
Faeth Therapeutics Inc Stock (SNSE) Financials Data
Revenue
Net Income
Cash Flow
EPS
Faeth Therapeutics Inc Stock (SNSE) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Peyer James | 10% Owner |
Jun 01 '26 |
Sale |
20.02 |
25,000 |
500,543 |
130,142 |
| MILLENNIUM MANAGEMENT LLC | 10% Owner |
Apr 02 '26 |
Buy |
35.01 |
2,003 |
70,133 |
144,974 |
| MILLENNIUM MANAGEMENT LLC | 10% Owner |
Apr 07 '26 |
Buy |
33.38 |
1,108 |
36,985 |
133,986 |
| MILLENNIUM MANAGEMENT LLC | 10% Owner |
Apr 06 '26 |
Buy |
31.02 |
1,104 |
34,246 |
141,029 |
| MILLENNIUM MANAGEMENT LLC | 10% Owner |
Apr 07 '26 |
Sale |
31.01 |
8,151 |
252,775 |
133,986 |
| MILLENNIUM MANAGEMENT LLC | 10% Owner |
Apr 02 '26 |
Sale |
32.12 |
7,666 |
246,239 |
144,974 |
| MILLENNIUM MANAGEMENT LLC | 10% Owner |
Apr 06 '26 |
Sale |
31.06 |
1,259 |
39,100 |
141,029 |
| MILLENNIUM MANAGEMENT LLC | 10% Owner |
Apr 01 '26 |
Buy |
34.49 |
6,175 |
212,979 |
147,731 |
| MILLENNIUM MANAGEMENT LLC | 10% Owner |
Mar 31 '26 |
Buy |
28.16 |
6,005 |
169,121 |
146,657 |
| MILLENNIUM MANAGEMENT LLC | 10% Owner |
Mar 31 '26 |
Sale |
25.49 |
1,591 |
40,553 |
146,657 |
0.40%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):